All times are listed in CEST (Central European Summer Time)

Displaying One Session

Proffered Paper session
Date
Sat, 10.09.2022
Time
10:15 - 11:45
Location
7.2.E - Évry Auditorium
Chairs
  • Peter Dubsky (Luzern, Switzerland)
  • Ana Bosch (Malmo, Sweden)
Session Type
Proffered Paper session
Proffered Paper session

133O - Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial

Presentation Number
133O
Speakers
  • Vivianne C. Tjan-Heijnen (Maastricht, Netherlands)
Lecture Time
10:15 - 10:25
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45

Abstract

Background

The DATA study evaluated the use of different durations of anastrozole in patients with hormone receptor-positive breast cancer who were disease-free after 2-3 years of tamoxifen. Here, we present the final analysis.

Methods

The DATA study was a phase III, open-label, randomised controlled trial performed in 79 hospitals in the Netherlands. Postmenopausal women with hormone receptor-positive breast cancer who were disease-free after 2-3 years of adjuvant tamoxifen received either 3 or 6 years of anastrozole in a 1:1 ratio. Randomisation was stratified by nodal status, hormone receptor status, HER2 status and duration of prior tamoxifen treatment. The primary endpoint was adapted disease-free survival (aDFS), defined as DFS from 3 years after randomisation onwards. Adapted overall survival (aOS) was evaluated as a secondary endpoint.

Results

Between June 2006 and August 2009, 1912 patients were randomly assigned to 3 or 6 years of anastrozole. Of these, 1660 patients were eligible and disease-free at 3 years after randomisation. The median adapted follow-up time was 10.1 years. The 10-year aDFS was 69% (95% confidence interval (CI): 66%-72%) in the 6-year group and 66% (95% CI: 63%-69%) in the 3-year group (hazard ratio 0.86; 95% CI: 0.72-1.01; p=0.073), with no difference in aOS (hazard ratio 0.93; 95% CI: 0.75-1.16; p=0.53). The effect of extended treatment on aDFS differed between patients with tumours expressing both oestrogen receptors (ER) and progesterone receptors (PR) (hazard ratio 0.77; 95% CI: 0.63-0.94; p=0.008), and patients with tumours expressing only one receptor (hazard ratio 1.22; 95% CI: 0.86-1.73; p=0.28) (p interaction=0.018). In patients with node-positive, ER- and PR-positive tumours (n=849), the 10-year aDFS was 69% (95% CI: 64%-73%) in the 6-year group and 61% (95% CI: 56%-65%) in the 3-year group (hazard ratio 0.74; 95% CI: 0.59-0.93; p=0.011), with no significant difference in aOS (hazard ratio 0.84; 95% CI: 0.62-1.12; p=0.23).

Conclusions

We cannot recommend extending aromatase inhibition beyond 5 years of sequential therapy in all postmenopausal women with hormone receptor-positive breast cancer. It may however be considered in patients with node-positive, ER- and PR-positive tumours.

Clinical trial identification

NCT00301457.

Legal entity responsible for the study

Maastricht UMC+.

Funding

AstraZeneca.

Disclosure

V.C.G. Tjan-Heijnen: Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Novartis, Eli Lilly, Pfizer, Eisai, Daiichi Sankyo, Gilead; Financial Interests, Personal, Advisory Role: Pfizer, Eli Lilly, Accord, Novartis; Financial Interests, Personal, Other, Honorarium: Novartis, Roche, Eli Lilly, AstraZeneca. S.W.M. Lammers: Financial Interests, Institutional, Research Grant: AstraZeneca. S.M.E. Geurts: Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Pfizer, Novartis, Eli Lilly, Daiichi Sankyo, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca. I.J.H. Vriens: Financial Interests, Institutional, Research Grant: AstraZeneca, Pfizer; Financial Interests, Personal, Advisory Board: Pfizer, Novartis. A.C.P. Swinkels: Financial Interests, Institutional, Research Grant: AstraZeneca. J.R. Kroep: Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Philips. A.H. Honkoop: Financial Interests, Institutional, Research Grant: Dutch Breast Cancer Research Group; Financial Interests, Personal, Advisory Board: Eli Lilly. S.C. Linn: Financial Interests, Institutional, Advisory Board: AstraZeneca, Cergentis, IBM, Novartis, Pfizer, Roche, Sanofi; Financial Interests, Institutional, Research Grant: Agendia, Amgen, AstraZeneca, Eurocept Pharmaceuticals, Genentech, Immunomedics, Merck, Roche, Sanofi, TESARO; Financial Interests, Institutional, Funding: Bayer, Daiichi Sankyo; Other, Institutional, Ownership Interest, Patent application: BRCA-like ovarian cancer classifier. A.L.T. Imholz: Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session

LBA13 - Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

Presentation Number
LBA13
Speakers
  • Marleen Kok (Amsterdam, Netherlands)
Lecture Time
10:25 - 10:35
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45

Abstract

Background

Immune checkpoint blockade (ICB) added to neoadjuvant chemotherapy (CTx) improves outcome for early stage TNBC patients, but it is largely unknown which patients truly benefit from ICB and for whom CTx can be de-escalated. Moreover, the addition of anti-CTLA4 to anti-PD1 has not been explored in early TNBC. In the first two cohorts of the adaptive phase II BELLINI trial we test the hypothesis that 4 weeks of neoadjuvant nivolumab (nivo) ± low dose ipilimumab (ipi, 1mg/kg) can induce immune responses in TNBC harboring TILs (TILs≥5%).

Methods

Stage I-III TNBC patients were treated with nivo (2 cycles, n=16) or nivo/ipi (2 cycles nivo, 1 cycle ipi, n=15) before start of neoadjuvant CTx or surgery. Primary endpoint is immune activation defined as 2-fold change (2FC) in CD8+ T cells or 2FC IFNG expression increase after 4 weeks. Secondary endpoints included safety, radiological response (RECIST1.1) and translational analyses. According to Simon’s two-stage design, immune activation in 30% of the patients allows expansion of a cohort.

Results

A partial radiological response (PR) after 4 weeks was evident in 7/31 (23%) patients, of which 3 received nivo and 4 nivo/ipi. In the 3 patients that went for surgery after ICB, we observed 1 pCR and 1 near-pCR. Only 6% of the patients developed a grade 3-4 adverse event. Immune activation was detected in 18/31 patients (58%), of which 9 received nivo and 9 nivo/ipi. All patients with a PR had TIL levels above 40%. Patients with a PR had higher baseline expression of IFNG (p=0.014). While baseline CD8+ T cell levels did not correlate with response, spatial analyses revealed that having CD8+ T cells more adjacent to tumor cells was strongly associated with response (p=0.0014). ctDNA clearance at 4 weeks was evident in 24% of the patients.

Conclusions

The majority of TNBC patients with TILs showed increased immune activation after only 4 weeks of ICB and a substantial fraction experienced a clinical response, highlighting the potential of ICB without CTx for TNBC patients.

Clinical trial identification

EudraCT: 2018-004188-30.

Legal entity responsible for the study

Netherlands Cancer Institute.

Funding

Bristol-Myers Squibb, NWO (VIDI), Natera.

Disclosure

R.F. Salgado: Non-Financial Interests, Institutional, Invited Speaker: Merck, BMS; Financial Interests, Institutional, Sponsor/Funding: Merck, Puma Biotechnology, Roche; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Personal, Advisory Role: Roche. K. Van De Vijver: Non-Financial Interests, Institutional, Advisory Board: GSK, AstraZeneca, ExactSciences. E. Kalashnikova: Financial Interests, Personal, Full or part-time Employment: Natera; Financial Interests, Personal, Stocks/Shares: Natera. S. Willingham: Financial Interests, Personal, Full or part-time Employment: Natera; Financial Interests, Personal, Stocks/Shares: Natera. G.S. Sonke: Financial Interests, Institutional, Sponsor/Funding: Merck, Agendia, AstraZeneca, Roche, Novartis; Non-Financial Interests, Institutional, Advisory Role: Novartis, Seattle Genetics, Biovica. C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre; Financial Interests, Personal, Expert Testimony: Third Rock Ventures; Financial Interests, Personal, Stocks/Shares: Uniti Cars, co-founder Immagene BV; Financial Interests, Institutional, Invited Speaker: BMS, Novartis, NanoString, 4SC. R. Mann: Financial Interests, Institutional, Advisory Role: BD, Bayer, Screenpoint, Seno Medical, Koning, Medtronic. S.C. Linn: Financial Interests, Institutional, Sponsor/Funding: Roche, AstraZeneca, BMS, Tesaro, Merck, Immunomedics, Eurocept, Agendia, Novartis; Financial Interests, Institutional, Advisory Role: Daiichi Sankyo. M. Kok: Financial Interests, Institutional, Sponsor/Funding: BMS, Roche, AstraZeneca; Non-Financial Interests, Institutional, Advisory Role: BMS, Roche, MSD, Daiichi Sankyo. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session

Invited Discussant 133O and LBA13

Speakers
  • Lucia Del Mastro (Genova, Italy)
Lecture Time
10:35 - 10:45
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45
Proffered Paper session

Q&A

Speakers
  • All Speakers (Lugano, Switzerland)
Lecture Time
10:45 - 11:00
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45
Proffered Paper session

LBA14 - Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials

Presentation Number
LBA14
Speakers
  • Oleg Gluz (Mönchengladbach, Germany)
Lecture Time
11:00 - 11:10
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45

Abstract

Background

Benefit of chemotherapy (CT) addition to ET remains controversial in premenopausal (pre) patients (pts) with 0-3 positive LNs (N0-1) and RS ≤25. In ADAPT, excellent outcome was observed in young N0-1 pts and ET response after short-term preoperative ET and RS 12-25 with ET alone. Here, we investigate impact of age, RS, and OFS on ET response, in ADAPT and its validation in the first part of ongoing phase III ADAPTcycle trial.

Methods

In ADAPT, pts with clinical high-risk HR+/HER2- EBC received 3w of induction standard ET prior to surgery or core biopsy, and then ET-alone if N0-1 and RS 0-11 or 12-25 ± post-endocrine Ki67post≤10%, or CT if Ki67post>10%. In ADAPTcycle (n=5000 to screen), N0-1 pts with RS>25 and Ki67post≤10% and N2-3 pts with RS≤25 and ET-response are randomized to (neo)adjuvant CT or AI+ribociclib.

Results

5938 pts included (ADAPT, n=3666; Acycle, n=2272): 1975 pts ≤50y/pre, 424 pts ≤40y. ET in ≤50y/pre pts included tamoxifen (98% ADAPT, 70.4% Acycle), TAM+OFS (15.2% Acycle) and AI+OFS (14.4% Acycle); >80% of >50y or post pts had AI. Baseline ER did not differ significantly between age groups ≤40, >40-50- and >50 ys. Mean baseline RS scores were higher in pts ≤40ys, but comparable between pts aged >40-50 and >50. ET-response rates varied substantially by type of ET, age, and RS in particular if no OFS in premenopausal pts. In ADAPT, ET-response was associated with improved iDFS in all age cohorts, independent of baseline Ki67.

Age subgroup RS 0-25 (ADAPT/A-Cycle) Endocrine Response Ki67post<= 10% (%) RS>25 (ADAPT/A-cycle) Endocrine Response Ki67post<= 10% (%)
Tam TAM+ OFS* AI+ OFS* AI TAM TAM+ OFS* AI+ OFS* AI
≤50 years and premenopausal 45.1/ 37.6% 65.0% 76.5% 14.3/ 19.5% 48.0% 77.8%
≤40 years 37.7/ 41.7% 72.2% 84.6% 3.9/ 14.3% 44.4% 69.2%
41-50 years 46.8/ 36.8% 61.9% 74.6 17.8/ 21.8% 52.2% 82.6%
>50 years old or postmenopausal 61.7/ 49.7% ** ** 88.6/ 85.8% 21.5/ 15.2% ** ** 44.6/ 64.7%

* OFS data in ADAPTCycle only, in ADAPT, only 2% AI+OFS in pts ≤50 ys ** only few pts treated by OFS in >50 ys, pre group

Conclusions

ET-response after TAM or AI according to RS groups was similar in both trials, but adding OFS to TAM or AI substantially improves ET-response in pre pts ≤ 50y, rendering similar results as in AI-treated post pts. ET-response assessment provides clinically relevant information for CT-decision making in pre ≤50y N0-1 pts in addition to gene expression testing.

Clinical trial identification

NCT01779206.

Legal entity responsible for the study

West German Study Group.

Funding

Exact Science, Novartis, Amgen, Bristol Myers Squibb.

Disclosure

O. Gluz: Financial Interests, Personal, Advisory Board: Roche, Lilly, Amgen, Novartis, Pierre Fabre, MSD, Celgene, Pfizer, Gilead, Molecular Health, Seagen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Exact Science; Financial Interests, Institutional, Invited Speaker: Roche; Non-Financial Interests, Leadership Role: West German Study Group; Non-Financial Interests, Personal, Proprietary Information: West German Study Group. U.A. Nitz: Financial Interests, Institutional, Other, Honoraria: Agendia, Amgen, Celgene, Genomic Health, Nanostring Technologies, Novartis Pharma, Pfizer Pharmaceuticals, Roche/Genentech, Teva; Financial Interests, Institutional, Advisory Role: Genomic Health, Roche, Seagen; Financial Interests, Institutional, Funding: Agendia, Amgen, Celgene, Genomic Health, Nano String Technologies, Roche, Sanofi; Financial Interests, Institutional, Expert Testimony: Genomic Health; Financial Interests, Institutional, Other, Travel Expenses: Genomic Health, Pfizer Pharmaceuticals, Roche; Other, Institutional, Other, Co-Director: WSG. S. Kuemmel: Financial Interests, Institutional, Advisory Role: Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Genomic Health/Exact Sciences, Lilly, MSD, Novartis, Seagen, Lilly, Pfizer, pfm Medical, Roche, Somatex, Gilead; Financial Interests, Institutional, Funding: Roche, Novartis; Financial Interests, Institutional, Other, Travel Expenses: Roche, Daiichi Sankyo; Financial Interests, Institutional, Other, Non-CME Services: Somatex, Roche, Novartis, Lilly; Financial Interests, Institutional, Other, Personal Fees: Roche, Novartis; Financial Interests, Institutional, Ownership Interest, WSG: WSG; Financial Interests, Institutional, Other, Co-Director: WSG. M. Braun: Financial Interests, Institutional, Other, Honoraria: AstraZeneca, Exact Sciences, Novartis, Pfizer, Roche, Teva, MSD; Financial Interests, Institutional, Advisory Role: AstraZeneca, Exact Sciences, Novartis, Puma, Roche; Financial Interests, Institutional, Other, Travel Expenses: AstraZeneca, Celgene, Medac, Novartis, Roche, Daiichi Sankyo. M. Thill: Financial Interests, Institutional, Other, Honoraria: Amgen, AstraZeneca, Celgene, Clovis, Eisai, Exact Sciences, Daiichi Sankyo, GSK, Hexal, Lilly, Medtronic, MSD, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical; Financial Interests, Institutional, Advisory Role: Amgen, AstraZeneca, Biom'Up, Celgene, ClearCut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Lilly, MSD, Norgine, Neodynamics, Novartis, Pfizer, pfm Medical, Pierre-Fabre, Roche, RTI Surgical, Sysmex; Financial Interests, Institutional, Funding: Exact Sciences, Neodynamics, RTI Surgical; Financial Interests, Institutional, Other, Travel Expenses: Amgen, Celgene, Exact Sciences, pfm Medical, Roche; Financial Interests, Institutional, Other: Celgene, ClearCut, Roche, pfm Medical. B. Aktas: Financial Interests, Institutional, Other, Honoraria: Pfizer, Roche Pharma, Merck Sharp & Dohme, Onkowissen.de, Novartis Pharma, AsstraZeneca, PharmaMar, Lilly, promedicis. P. Wimberger: Financial Interests, Other, Honoraria: Amgen, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Teva, Eisai, Clovis, GSK; Financial Interests, Advisory Board: Amgen, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Teva, Eisai, Clovis, GSK; Financial Interests, Funding: Amgen, AstraZeneca, MSD, Novartis, Pfizer, Roche, Clovis, GSK. M. Zaiss: Financial Interests, Advisory Role: Roche, Jannsen, Novartis, AstraZeneca, Gilead, AbbVie; Financial Interests, Speaker’s Bureau: Roche, Pfizer. M. Graeser: Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Other, Travel Expenses: Daiichi Sankyo, AstraZeneca; Financial Interests, Institutional, Member: WSG. A.D. Hartkopf: Financial Interests, Institutional, Other, Honoraria: AstraZeneca, Agendia, Amgen, Clovis, Daichii Sankyo, Eisai, Exact Sciences, Gilead, GSK, Lilly, Hexal, MSD, Novartis, Onkowissen, Pfizer, Roche, Pierre Fabre, Seagen; Financial Interests, Institutional, Advisory Role: AstraZeneca, Agendia, Amgen, Clovis, Daichii Sankyo, Eisai, Exact Sciences, Gilead, GSK, Lilly, Hexal, MSD, Novartis, Onkowissen, Pfizer, Roche, Pierre Fabre, Seagen; Financial Interests, Institutional, Funding: Exat Sciences; Financial Interests, Institutional, Other, Travel Expenses: Pfizer, Roche, Gilead, AstraZeneca; Financial Interests, Institutional, Speaker’s Bureau: AstraZeneca, Eisai, Exact Sciences, Gilead, GSK, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. R.E. Kates: Financial Interests, Institutional, Other, Honoraria: Amgen, AstraZeneca, Genomic Health, Novartis, Pfizer, Roche, Zodiac Pharma; Financial Interests, Institutional, Advisory Role: AstraZeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen; Financial Interests, Institutional, Funding: WSG. P. Schmid: Financial Interests, Institutional, Research Grant: Astellas Pharma, AstraZeneca, Medivation Inc.; Financial Interests, Institutional, Advisory Role: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, F. Hoffmann - La Roche, Merck; Financial Interests, Personal, Research Grant: F. Hoffmann - La Roche, Genentech, Novartis; Financial Interests, Institutional, Advisory Role, Honoraria: Novartis; Financial Interests, Other, Data and Safety Monitoring: Novartis; Financial Interests, Institutional, Funding: OncoGenexPharmaceuticals, Inc.; Financial Interests, Advisory Role: Pfizer; Financial Interests, Advisory Role, Honoraria: Puma Biotechnology. H. Kreipe: Financial Interests, Other, Honoraria: Roche Pharma, Novartis, Genomic Health, AstraZeneca, Lilly, Pfizer; Financial Interests, Advisory Role: Roche Pharma, Genomic Health, AstraZeneca. N. Harbeck: Financial Interests, Other, Honoraria: AstraZeneca, Genomic Health, Amgen, Novartis, Pfizer, Pierre Fabre, Roche, Zodiac Pharma; Financial Interests, Advisory Role: AstraZeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen; Financial Interests, Institutional, Funding: Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech; Financial Interests, Other, Fees for Non-CME Services: Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, MSD, Novartis, Pierre Fabre, Pfizer, Roche, SeaGen; Financial Interests, Ownership Interest, WSG: WSG; Financial Interests, Other, Co-Director: WSG. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session

134O - Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)

Presentation Number
134O
Speakers
  • Lucia Del Mastro (Genova, Italy)
Lecture Time
11:10 - 11:20
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45

Abstract

Background

The GIM 2 trial compared in a 2x2 factorial design the dose dense (DD, every 2 weeks) schedule to the standard interval one (every 3 weeks) and the addition of fluorouracil (F) to epirubicin-cyclophosphamide (EC) and paclitaxel (P) as adjuvant chemotherapy for node-positive breast cancer. In the primary analysis (Del Mastro, Lancet 2015), disease-free survival (DFS) and overall survival (OS) were significantly improved with the DD schedule, while no benefit was observed with the addition of F. Here, we report the end-of-study analysis.

Methods

This was an open-label, phase III trial, done in 81 Italian centres. Node-positive breast cancer patients were randomly allocated 1:1:1:1 to receive either EC-P or FEC-P DD or standard-interval EC-P or FEC-P The primary endpoint was DFS, comparing FEC-P vs. EC-P, and DD vs. standard-interval schedule. Secondary end points included OS and safety.

Results

2091 patients were randomized; 88 patients were enrolled in centres providing only standard-intensity schedule. After a median follow-up of 15.11 years (IQR 8.40-16.33), 343 of 1002 patients (34.2%) and 409 of 1001 patients (40.9%) in the DD and control arm experienced a DFS event, with 15-year DFS of 61% (95% CI 58-64) and 52% (95%CI 49-56), respectively (Hazard Ratio [HR] 0.77, 95% CI 0.67-0.89; p<0.001). 197 (19.7%) and 254 (25.4%) OS events were registered, with 15-years OS of 76% (95%CI 73-79) and 69% (95%CI 65-72) in the DD and control arm, respectively (HR 0.72, 95%CI 0.60-0.86, p<0.001). Addition of F did not significantly improve DFS (HR 1.12, 95%CI 0.98-1.29, p= 0.11) and OS (HR 1.13, 95%CI 0.94-1.36, p=0.18).

In hormone receptor-positive (N=1611), 15-years OS was 76% (95% CI 72-79) with the DD and 71% (95% CI 67-74) with the standard schedule. For hormone receptor-negative (N=335), 15-years OS was 76% (95%CI 69-83) with the DD and 63% (95%CI 55-71) with the standard schedule. Four cases of myelodysplasia/leukaemia were observed.

Conclusions

The final analysis confirmed an improved DFS and OS with the use of DD as compared with the standard schedule. The DD should be considered the standard adjuvant schedule for node-positive breast cancer patients.

Clinical trial identification

NCT00433420.

Legal entity responsible for the study

The authors.

Funding

Bristol-Myers Squibb; Pharmacia, and Dompè Biotec.

Disclosure

L. Del Mastro: Financial Interests, Personal, Invited Speaker, Educational meeting: Novartis, Symposia, Andromeda E20, Vyvamed srl; Financial Interests, Personal, Invited Speaker, Lecture: Ipsen; Financial Interests, Personal, Advisory Board, Her2+ and TN breast cancer: Roche; Financial Interests, Personal, Invited Speaker, Consultancy for TNBC text: Roche; Financial Interests, Personal, Advisory Board, denosumab: Amgen; Financial Interests, Personal, Advisory Board, Early and metastatic BC: Eli Lilly; Financial Interests, Personal, Invited Speaker, CDK4-6 inhibitors: Eli Lilly; Financial Interests, Personal, Advisory Board, tucatinib: Seagen Int; Financial Interests, Personal, Advisory Board, Oncotype dx: Exact sciences, Havas life; Financial Interests, Personal, Advisory Board, Neratinib: Pierre Fabre; Financial Interests, Personal, Invited Speaker, Internal training: MSD; Financial Interests, Personal, Invited Speaker, Educational meetings: Accademia Nazionale Medicina; Financial Interests, Personal, Invited Speaker, Author for BC text: Pensiero Scientifico Editore; Financial Interests, Personal, Advisory Board, Breast cancer: Uvet; Financial Interests, Personal, Other, Author slide kits and interviews: Think2it; Financial Interests, Personal, Advisory Board, Palbociclib: Pfizer; Financial Interests, Personal, Invited Speaker, Breast cancer: Aristea, Meeting SrL; Financial Interests, Personal, Other, Author slide kits: Forum service; Financial Interests, Personal, Other, Author text about biosimilars: Edizioni Minerva Medica; Financial Interests, Personal, Other, consultant: Kardo srl; Financial Interests, Personal, Invited Speaker, Breast cancer meetings: Delphi international, Over srl; Financial Interests, Personal, Invited Speaker: Prex Srl, Editree; Financial Interests, Personal, Advisory Board: Uvet, Collage SpA, Daiichi Sankyo, Astrazeneca; Financial Interests, Personal, Other, Interview: Infomedica srl; Financial Interests, Personal, Other, Consultant: Sharing progress in cancer care - Switzerland; Financial Interests, Institutional, Funding, National coordinating PI: Roche; Financial Interests, Institutional, Funding, Local PI: AstraZeneca, Roche, Eli Lilly, Daiichi Sankyo, Novella Clinical, Novartis; Non-Financial Interests, Institutional, Product Samples, Genomic Test: FoundationOne. F. Poggio: Financial Interests, Personal, Invited Speaker: Novartis, Lilly, Pfizer. S. de Placido: Financial Interests, Invited Speaker: Novartis, Roche, Daichii Sankyo, Celgene, AstraZeneca, Pfizer, Eli Lilly, Eisai, MSD. M. Giuliano: Financial Interests, Invited Speaker: Eli Lilly, Novartis, Pfizer, Roche, MSD, Seagen, AstraZeneca. M. De Laurentiis: Financial Interests, Speaker’s Bureau: Amgen, AstraZeneca, Pierre Fabre Pharma; Financial Interests, Invited Speaker: Daichii Sankyo, Eisai, Eli Lilly, Exact Sciences, MSD, Novartis, Pfizer, Roche, Seagen; Financial Interests, Advisory Board: Gilead. O. Garrone: Financial Interests, Personal, Research Grant: Eisai; Financial Interests, Other: Pfizer; Financial Interests, Invited Speaker: Novartis, Amgen. C. Bighin: Financial Interests, Personal, Invited Speaker: Roche, Novartis, Eli Lilly. M. Mansutti: Financial Interests, Invited Speaker: Novartis, Pfizer, AstraZeneca, Eisai, MSD, Eli Lilly. F. Montemurro: Financial Interests, Invited Speaker: Roche, Eli Lilly, Seagen, Novartis, Pfizer, Pierre Fabre. M. Lambertini: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Lilly, Novartis, Exact Sciences, MSD, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: Pfizer, Takeda, Sandoz, Ipsen, Libbs, Knight. All other authors have declared no conflicts of interest.

Collapse
Proffered Paper session

Invited Discussant LBA14 and 134O

Speakers
  • Peter Dubsky (Luzern, Switzerland)
Lecture Time
11:20 - 11:30
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45
Proffered Paper session

Q&A

Speakers
  • All Speakers (Lugano, Switzerland)
Lecture Time
11:30 - 11:45
Location
7.2.E - Évry Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
10:15 - 11:45